- Home
- MEIP vs TRUE Comparison
MEIP vs TRUE Comparison
Compare MEIP & TRUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- TRUE
- Stock Information
- Founded
- MEIP 2000
- TRUE 2005
- Country
- MEIP United States
- TRUE United States
- Employees
- MEIP N/A
- TRUE N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- TRUE Computer Software: Programming Data Processing
- Sector
- MEIP Health Care
- TRUE Technology
- Exchange
- MEIP Nasdaq
- TRUE Nasdaq
- Market Cap
- MEIP 153.9M
- TRUE 171.0M
- IPO Year
- MEIP 2003
- TRUE 2014
- Fundamental
- Price
- MEIP $3.00
- TRUE $2.20
- Analyst Decision
- MEIP
- TRUE Buy
- Analyst Count
- MEIP 0
- TRUE 5
- Target Price
- MEIP N/A
- TRUE $3.19
- AVG Volume (30 Days)
- MEIP 790.3K
- TRUE 318.7K
- Earning Date
- MEIP 09-23-2025
- TRUE 11-05-2025
- Dividend Yield
- MEIP N/A
- TRUE N/A
- EPS Growth
- MEIP N/A
- TRUE N/A
- EPS
- MEIP N/A
- TRUE N/A
- Revenue
- MEIP N/A
- TRUE $184,559,000.00
- Revenue This Year
- MEIP N/A
- TRUE $7.65
- Revenue Next Year
- MEIP N/A
- TRUE $6.39
- P/E Ratio
- MEIP N/A
- TRUE N/A
- Revenue Growth
- MEIP 33.76
- TRUE 11.66
- 52 Week Low
- MEIP $1.46
- TRUE $1.05
- 52 Week High
- MEIP $9.00
- TRUE $4.62
- Technical
- Relative Strength Index (RSI)
- MEIP 26.36
- TRUE 61.83
- Support Level
- MEIP $3.85
- TRUE $2.02
- Resistance Level
- MEIP $5.50
- TRUE $2.31
- Average True Range (ATR)
- MEIP 0.37
- TRUE 0.12
- MACD
- MEIP -0.20
- TRUE 0.02
- Stochastic Oscillator
- MEIP 3.10
- TRUE 78.64
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About TRUE TrueCar Inc.
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. The Company has one operating segment, with three distinct service offerings: Dealer products and services, OEM incentives, and other.